OBJECTIVES: Generate preliminary estimates of active health care professional (HCP) time required /potential time and cost savings between SC vs. IV rituximab processes at the care unit and pharmacy in sites participating in T&M sub-study to MO25455 trial (ClinicalTrials.gov identifier NCT01461928). METHODS: As part of an ongoing multi-country, multi-centre, prospective, T&M study run as a sub-study to MO25455, one interview with a nurse and pharmacy member was conducted per site, using a structured questionnaire to elicit practice pattern flow and time estimates for rituximab-related tasks for both IV and SC processes. Estimates of SC injection time were obtained from the Spark-Thera Phase Ib trial (BP22333) (in the absence of staff-elicited time estimates). Estimated total time/cost was calculated as the sum of individual task times/costs. UK salary costs were assumed. Results were pooled and descriptive statistics were calculated. RESULTS: Median total HCP time for IV vs. SC processes was estimated at 57 and 26 minutes, respectively, equivalent to approximately £79 and £37 (estimated 54% reduction with SC). For IV, process time is taken up by premedication (27%) and rituximab pharmacy reconstitution (18%), with the remaining 55% distributed across other care unit tasks. For SC, premedication (57%), injection (24%) and rituximab pharmacy dispensing (19%) constitute the whole process. Potential time savings are expected because of avoiding tasks related mainly to infusion line (dis)connection, infusion initiation/dose escalations, and IV pharmacy reconstitution, which is only partially being replaced by SC injection. CONCLUSIONS: A switch from IV to SC rituximab potentially results in important care unit and pharmacy time savings to be reinvested in improving overall patient care. Patients could potentially be moved out of the chemotherapy care unit to receive SC administration in other settings and free up valuable chair time, thereby increasing the unit’s throughput and overall efficiency. Data of the T&M study is awaited.